15 completed, 4 terminated, 1 recruiting. 20 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 20 | Completed 15, Terminated 4, Recruiting 1 |
| Phase 2 | 4 | Completed 4 |
Follow ambrisentan: new trials by email Literature Review of ambrisentan trials Research Report on ambrisentan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities Tadalafil, Ambrisentan, Placebo (Ambrisentan-matching) - Pulmonary Arterial Hypertension (PAH), Comorbidities | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 186 | 2026-04-28 | 2026-05-13 |
| mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms EDP1815, Dapagliflozin, Ambrisentan - COVID-19 | Phase 2 / Phase 3 | Completed | Cambridge University Hospitals NHS Foundation Trust | 454 | 2020-07-03 | 2023-07-28 |
| Efficacy and Safety Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension Ambrisentan - Pulmonary Arterial Hypertension | Phase 3 | Completed | RenJi Hospital | 80 | 2018-12-18 | 2022-06-29 |
| A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Ambrisentan 5 mg - Hypertension | Phase 3 | Terminated | GlaxoSmithKline | 19 | 2014-01-23 | 2017-09-11 |
| Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension. Ambrisentan 5 mg, Placebo - Hypertension | Phase 3 | Terminated | GlaxoSmithKline | 33 | 2013-09-01 | 2017-03-06 |
| Drug Combination on Exercise Performance at High Altitude ambrisentan and theophylline, placebo - Acute Mountain Sickness | Phase 2 / Phase 3 | Completed | University of Montana | 28 | 2013-08-01 | 2016-02-26 |
| Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH) ambrisentan - Vascular Disease | Phase 3 | Completed | GlaxoSmithKline | 134 | 2012-12-01 | 2017-06-06 |
| Characterization and Detection of Prolonged Endothelin Receptors Antagonists Administration Bosentan, Ambrisentan, Placebo - Pulmonary Hypertension | Phase 2 / Phase 3 | Completed | Center for Health Sciences, Serbia | 30 | 2011-01-01 | 2013-05-08 |
| A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) ambrisentan, tadalafil - Hypertension, Pulmonary | Phase 3 | Completed | GlaxoSmithKline | 610 | 2010-10-01 | 2017-09-13 |
| Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial Ambrisentan - Portopulmonary Hypertension | Phase 3 | Completed | Tufts Medical Center | 30 | 2010-03-01 | 2021-01-12 |
| ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis Ambrisentan, Placebo - Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension | Phase 3 | Terminated | Gilead Sciences | 40 | 2009-07-01 | 2014-05-15 |
| (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF Ambrisentan, Placebo - Idiopathic Pulmonary Fibrosis | Phase 3 | Terminated | Gilead Sciences | 494 | 2008-12-01 | 2014-04-08 |
| Study of Ambrisentan in Participants With Pulmonary Hypertension Ambrisentan - Pulmonary Hypertension | Phase 3 | Completed | Gilead Sciences | 140 | 2008-11-17 | 2020-09-30 |
| Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension Ambrisentan - Sarcoidosis, Pulmonary Hypertension | Phase 2 / Phase 3 | Completed | Medical University of South Carolina | 16 | 2008-11-01 | 2018-08-02 |
| A Study to Evaluate GSK1325760A - a Long-Term Extension Study GSK1325760A - Pulmonary Arterial Hypertension, Hypertension, Pulmonary | Phase 3 | Completed | GlaxoSmithKline | 21 | 2008-02-01 | 2012-11-05 |
| Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension Ambrisentan - Pulmonary Hypertension | Phase 3 | Completed | Gilead Sciences | 224 | 2006-08-01 | 2012-04-05 |
| A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202) ambrisentan - Pulmonary Arterial Hypertension | Phase 3 | Completed | Gilead Sciences | 383 | 2004-02-01 | 2013-01-15 |
| ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH) Ambrisentan - Pulmonary Hypertension | Phase 3 | Completed | Gilead Sciences | 372 | 2004-01-01 | 2010-03-08 |
| Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension. ambrisentan - Pulmonary Arterial Hypertension | Phase 3 | Completed | Gilead Sciences | 186 | 2003-12-01 | 2009-04-16 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension. ambrisentan - Pulmonary Arterial Hypertension | Phase 3 | Completed | Gilead Sciences | 186 | 2003-12-01 | 2009-04-16 |
Hypertension, Pulmonary (8) · Pulmonary Arterial Hypertension (8) · Hypertension (2) · Idiopathic Pulmonary Fibrosis (2) · Altitude Sickness (1) · COVID-19 (1) · Cardiovascular Diseases (1) · Dyspnea (1) · Esophageal and Gastric Varices (1) · Hypertension, Portal (1) · Lung Diseases, Interstitial (1) · Sarcoidosis (1) · Vascular Diseases (1)
Gilead Sciences (8) · GlaxoSmithKline (5) · Assistance Publique - Hôpitaux de Paris (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Center for Health Sciences, Serbia (1) · Medical University of South Carolina (1) · RenJi Hospital (1) · Tufts Medical Center (1) · University of Montana (1)
United States (11) · Canada (8) · Australia (6) · United Kingdom (6) · Argentina (5) · Austria (5) · Germany (5) · Mexico (5) · China (4) · Japan (4) · Netherlands (4) · Spain (4) · Brazil (3) · Chile (3) · Czechia (3)
Chris Dufton, PhD (1) · Don C Rockey, MD (1) · Ganesh Raghu, MD (1) · Hunter Gillies, M.D. (1) · Ioana Preston, MD (1) · Jieyan Shen, PhD (1) · Joseph Cheriyan, MBChB MA FRCP (1) · Lewis J Rubin, MD (1) · Lewis J. Rubin, MD (1) · Marc A Judson, MD (1) · Sergej M Ostojic, MD, PhD (1)
PMID 18506008, PMID 19909879, PMID 22506623, PMID 23648946, PMID 24177001, PMID 24342407, PMID 24717624, PMID 25613108, PMID 26196225, PMID 26308684, PMID 27770771, PMID 28039187, PMID 31511080, PMID 32008947, PMID 32161055, PMID 32680480, PMID 32736592, PMID 32799568, PMID 34473343, PMID 37378404
2023 (1)